| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 224 | 178 | -1,163* | -333 |
| Asset impairment | - | - | 0* | 0 |
| General and administrative | 946 | 880 | 1,332* | 957 |
| Total operating expenses | 1,170 | 1,058 | 168 | 624 |
| Loss from operations | -1,170 | -1,058 | -168* | -624 |
| Other income | - | - | 0* | 0 |
| Interest income, net | 98 | 103 | 93* | 156 |
| Total other income | 98 | 103 | 93* | 156 |
| Net loss | -1,072 | -955 | -76 | -468 |
| Basic EPS | -0.16 | -0.14 | -0.015 | -0.07 |
| Diluted EPS | -0.16 | -0.14 | -0.015 | -0.07 |
| Basic Average Shares | 6,732,970 | 6,729,855 | 4,908,164* | 6,241,658 |
| Diluted Average Shares | 6,732,970 | 6,729,855 | 4,908,164* | 6,241,658 |
MUSTANG BIO, INC. (MBIO)
MUSTANG BIO, INC. (MBIO)